Jakafi and Zometa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Jakafi (ruxolitinib phosphate) and Zometa (zoledronic acid). Common drug interactions include fall among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Jakafi and Zometa. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

14 people who take Jakafi and Zometa together, and have interactions are studied.

What are the common drug interactions of Jakafi and Zometa, by gender? *:

female:

Fall
Muscle spasms (muscle contraction)
Headache (pain in head)
Dyspnoea (difficult or laboured respiration)
Head injury
Infection
Anxiety
Back pain
Blood immunoglobulin g decreased
Cachexia (loss of weight)

male:

Fatigue (feeling of tiredness)
Acute myocardial infarction (acute heart attack)
Pain in extremity
Prostate cancer recurrent
Pyrexia (fever)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Transferrin decreased
Platelet count decreased
Osteitis (a general term for inflammation of bone)
Prostatic specific antigen increased

What are the common drug interactions of Jakafi and Zometa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Dyspnoea (difficult or laboured respiration)
Fall
Head injury
Infection
Muscle spasms (muscle contraction)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)

60+:

Fatigue (feeling of tiredness)
Acute myocardial infarction (acute heart attack)
Pain in extremity
Prostate cancer recurrent
Pyrexia (fever)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Transferrin decreased
Platelet count decreased
Osteitis (a general term for inflammation of bone)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

What are the existing conditions these people have? *

Weight Loss: 3 people, 21.43%
High Blood Pressure: 3 people, 21.43%
Dyspnea (difficult or laboured breathing): 3 people, 21.43%
Acute Myocardial Infarction (acute heart attack): 3 people, 21.43%
Infection: 2 people, 14.29%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 2 people, 14.29%
Urticaria Pigmentosa (skin disease that produces patches of darker skin (lesions) and very bad itching): 1 person, 7.14%
Splenomegaly (enlargement of spleen): 1 person, 7.14%
Prostate Cancer Metastatic: 1 person, 7.14%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and Zometa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously